In addition, Godara noted that toxicity management for bispecific antibodies has evolved. While early use of these therapies ...
A separate poster, drawing on data from the National Institutes of Health's All of Us Research Program, found that women with ...
Concurrent guideline statements have increased classification ambiguity, strengthening arguments for phenotype-first management rather than EF alone, particularly in infiltrative disease, chemotherapy ...
Overlapping environmental drivers include indoor cleaning chemicals, tobacco, biomass fuels, traffic pollution, occupational ...
Jorgen Vestbo, MD, discusses new COPERNICOS trial data showing COPD patients who do not meet a specific eosinophil threshold ...
Among cause-specific cardiovascular deaths, evolocumab showed directionally favorable effects for acute MI, stroke, and heart ...
US mortality surveillance mirrors the relative burden: 141,733 COPD deaths in 2023 outnumbered prostate and breast cancer ...
An all-oral, bedaquiline-containing regimen offers a potential salvage option for refractory MAC, reducing reliance on aminoglycoside therapy while requiring continued QT monitoring. "All-Oral ...
Behind every CAR T program is a real cost structure, staffing, drug stocking, and around-the-clock monitoring, that Dr. Graff breaks down as a practical barrier independent of clinical readiness. In ...
This episode, titled 'Expanding Access to Anti-Amyloid Therapy: The Case for Primary Care Prescribing,' featured panelists discussing the following critical questions: How are you enhancing ...
Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, ...
The FDA approved daraxonrasib (Rasonque), the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results